undamentalytics Newsletter
Sign in

Mirum Pharmaceuticals, Inc. income statement

In fiscal 2025, Mirum Pharmaceuticals, Inc. reported revenue of $521m, up 54.7% on the year before, operating income of −$22.1m (a -4.2% margin) and net income of −$23.4m, or −$0.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01977186337521618
Research and development82131107103141186283
Selling, general and administrative—5989146202257314
General and administrative23——————
Operating income−104−173−131−109−88−22−834
Interest expense——1615141413
Income before tax−103−84−142−162−87−21−858
Income tax00−61123
Net income−103−84−136−163−88−23−860
Diluted EPS−$4.09−$2.77−$4.02−$4.00−$1.85−$0.47−$15.33
Diluted shares (average)25m30m34m41m48m50m56m
EBITDA−104−173−128−98−642−808

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MIRM vs TARSARWR vs MIRMHCM vs MIRMMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mirum Pharmaceuticals, Inc.